^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Source:
Title:

Biomarker Modulation By Mivebresib (ABBV-075) +/– Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia

Published date:
11/06/2019
Excerpt:
Biologic activity was observed particularly in patients treated with MIV-VEN who had SF3B1/U2AF1 or PTPN11 mutations.
DOI:
https://doi.org/10.1182/blood-2019-126854
Trial ID: